News Release

Hip fracture patients in long-term care are less likely to receive osteoporosis therapy

Canadian study finds treatment gap in patients with prior hip fracture; knowledge transition strategies are needed to encourage improved secondary fracture prevention in all high-risk patients

Peer-Reviewed Publication

International Osteoporosis Foundation

Milan, Italy - March 28, 2015 Hip fractures, which primarily affect the elderly, are among the most debilitating and life-threatening of osteoporotic fractures: many hip fracture patients never regain their previous level of function and as a result require long-term care. Without osteoporosis therapy the risk of further, potentially more devastating hip fractures is high.

In a study presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, researchers in Ontario, Canada calculated the proportion of high-risk residents of long-term care (LTC) homes who were receiving osteoporosis medications and vitamin D supplementation according to specific high-risk categories. They assessed data for 6862 residents from 50 LTC homes in the province: 2949 (49%) were considered at high risk. Based on osteoporosis guidelines, high-risk was identified as individuals who had at least one spine/hip fracture, two or more non-hip/non-spine fractures, were currently taking corticosteroids; or had been previously diagnosed with osteoporosis.

Overall, there was a marked under-treatment of patients in all high-risk categories. It was found that residents with prior spine fractures, followed by residents who were taking corticosteroids were those more likely to receive drug therapy, while patients who had suffered a hip fracture were least likely to receive treatment.

The percentages of high risk patients receiving drug therapy for osteoporosis were as follows:

  • 47% of those with prior spine fracture
  • 34% of those with prior hip fracture
  • 38% of those with two or more non-hip or non-spine fractures
  • 43% who were taking glucocorticoids
  • 41% had a diagnosis of osteoporosis

Data showed that 77 % of the high-risk patients were on vitamin D therapy (800 mg/d or more).

The study was part of the Gaining Optimal Osteoporosis Assessments in Long-term Care (GOAL) initiative, developed to reduce fractures by utilizing multifaceted knowledge transition strategies.

Dr. George Ioannidis, researcher at the GERAS Centre and McMaster University and lead author of the study stated, "The study shows that there is a significant treatment gap in all categories of high risk patients, all of whom have suffered a previous fracture or are at high-risk due to glucocorticoids or a diagnosis of osteoporosis. It is interesting that those with prior hip fracture are those least likely to receive treatment. Given the potentially serious consequence of secondary fractures it is critical that all high-risk patients are considered for appropriate treatment. This care gap highlights the importance of developing guidelines for this high risk population - which is being led by the senior author Dr Alexandra Papaioannou."

The care gap identified in this Canadian study reflects similar findings around the world. In response, the International Osteoporosis Foundation (IOF) has established the Capture the Fracture® programme which provides recognition and guidance for the implementation of fracture liaison services, a proven way to reduce the care gap and prevent secondary fractures.


Reference: OC31 What triggers osteoporosis therapy in high risk residents living in long term care (LTC) homes? The Gaining Optimal Osteoporosis Assessments in Long-term Care (GOAL) study. G. Ioannidis, D. O'donnell, C. Kennedy et al. Osteoporosis International, Vol. 26, S 1. 2015.

This abstract will be highlighted in the WCO Milan 2015 educational slide set, to be available at

About IOF

The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers, leading companies, as well as more than 200 patient, medical and research societies, work together to make bone, joint and muscle health a worldwide heath care priority. / /


The European Society for Clinical & Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception.

About the World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases

Held jointly by IOF and ESCEO, the Congress is taking place in Milan, Italy from March 26-29, 2015. It is the world's largest annual forum for the presentation of clinical research and new advances in the prevention and management of bone, muscle and joint disorders. The next Congress will be held in Malaga, Spain from April 14-17, 2016. For complete information visit #OsteoCongress

Media contact

Charanjit K. Jagait, PhD
Communications Director, International Osteoporosis Foundation
Tel.: +41 22 994 01 02 * Mob.: +41 79 874 52 08

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.